Early-Career Researcher Cancer Immunotherapy Meeting

Thank you to everyone who attended! The meeting will be available to watch on-demand soon.


Thank you to everyone who attended! You can watch the meeting on-demand here.


Back by popular demand! The Proteintech events team is thrilled to announce that we are running our second Early-Career Researcher Cancer Immunotherapy Meeting. With international travel to conferences still uncertain, we want to provide a platform to young scientists to present their work to an international audience and help boost their visibility while presenting alongside leaders in their field. Our confirmed Keynote speakers are Dr Santiago Zelenay, from Cancer Research UK, Manchester and Dr Mike Chapman, from the Toxicology Unit, University of Cambridge, UK.

28th April 2022 3pm BST/ 4pm CEST/ 9am CDT.


 Download the meeting schedule here


2022 Keynote Speakers

Dr. Santiago Zelenay

Cancer Research UK, Manchester.

"Manipulating inflammation to raise cancer immunogenicity and the response to immunotherapy"

Dr Zelenay worked from 2008 at the CRUK London Research Institute and later at The Francis Crick Institute, where he investigated innate immune receptors and signaling pathways that trigger dendritic cell activation and drive T cell responses against viruses or tumours. In 2015, Dr Zelenay joined the CRUK Manchester Institute where he leads the Cancer Inflammation and Immunity Group. His group focuses on understanding the underlying mechanisms that mediate cancer-inhibitory versus tumour-promoting inflammation in order to design new therapies for cancer patients. In 2017, he received the CRUK Future Leaders in Cancer Research Prize.

Key publications: 

Pelly VS et al. 2021.
Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy. Cancer Discovery 11(10):2602-2619. PMID: 34031121)

Bonavita E et al. 2020. Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. Immunity 53, 1–15. PMID: 33220234

Böttcher JP et al. 2018. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172(5):1022-1037. Article

Dr. Mike Chapman

Toxicology Unit, University of Cambridge, UK.

"Biological Cancer Immunotherapies: Challenges at the Bench and at the Bedside".

Mike Chapman trained in Medicine at St. Bartholomew's and The Royal London Hospitals Medical Schools. He undertook a PhD with Bertie Göttgens and Tony Green in Cambridge investigating transcriptional regulation. He was a Post-Doc with Todd Golub at the Broad Institute in Cambridge, Massachusetts, where he ran a multiple myeloma genomics project, leading to the first high-throughput sequencing of a cancer patient cohort. He has run an independent research group since 2013. This was initially in the Department of Haematology at the University of Cambridge, but is now based in the MRC Toxicology Unit. His lab focuses on identifying and developing novel cancer immunotherapy targets and on better understanding the biology of cellular therapies. Mike also works as an honorary Consultant Haematologist at Addenbrookes hospital, with a clinical focus on multiple myeloma. 

Early-Career Speakers Announced!

We are excited to announce the 4 talented early-career cancer researchers who will be presenting their work at our Early-Career Researcher Cancer Immunotherapy Meeting.

Dr Peng Liao

Postdoctoral Research Fellow

University of Michigan

Talk title: "T cell-derived interrferon (IFN)γ in combination with arachidonic acid (AA) induces immunogenic tumor ferroptosis, serving as a mode of action for CD8+ T cells (CYL)-mediated tumor killing".

Katrin Pansy

PhD Student
Medical University of Graz, Austria
Talk title: "Loss of Nr4a1 is associated with higher expression of immune checkpoint components and reduced T cell-mediated lymphoma cell killing in aggressive lymphoma".

My Nguyen

PhD Student
Texas Tech University Health Sciences Center, United States
Talk title: "Listeria-based vaccine targeting interferon-stimulated gene 15 for renal cell carcinoma".

Dr Mary Priyankar Udumula

Postdoctoral Research Fellow
Henry Ford Health System, Detroit, United States
Talk title: "Targeting the alpha-ketoglutarate dehydrogenase complex reduces the immunosuppressive function of CD11b+Gr1+ myeloid cells and inhibits ovarian cancer growth".

For more information email events@ptglab.com 



Early-Career Researcher Meeting 2021

In 2021, Proteintech held our first ever Early-Career Researcher Meeting for Cancer Immunology. It was a huge success, with researchers tuning in to watch our speakers from across the globe. All the speakers gave excellent talks, and in particular the impressive results in the ECR talks highlight the importance of supporting all scientists in their work and giving them opportunities to showcase their talents. 

Watch the 2021 Early-Career Researcher Meeting for Cancer Immunology below.


Timestamps of recording: 

Dr John Maher: 02:25

Dr Matthias Bozza: 37:50

Dr John Lu: 59:45

Dr Rahul Mirlekar, Ms Maria Davern and Dr Ramona Moles have asked for their talks not to be included for intellectual property protection reasons.  


2021 Keynote Speakers

Dr. John Maher

Clinical Immunologist, Kings College London, UK

"CAR T-Cell Immunotherapy of Solid Tumors: Learning from the Clinic and Lab in Parallel"

Dr John Maher is a clinical immunologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development of second generation (CD28) CAR technology while a visiting fellow at Memorial Sloan Kettering Cancer Center, an approach that has achieved clinical impact in haematological malignancies. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells, with a primary emphasis on solid tumour types. He is also the scientific founder and chief scientific officer of a spin-out company named Leucid Bio. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital.

Dr. John Lu

President and CEO of HebeCell, USA

"CAR-NK Cells from Engineered Pluripotent Stem Cells; Off-The-Shelf Therapeutics for All Patients"

Dr. John Lu is currently the President and CEO of HebeCell Corporation. Established in 2016, HebeCell focuses on the fields of Immunotherapy and Regenerative Medicine. As a graduate from the Ontario Cancer institute, University of Toronto (PhD), John has 13 years of experience in cancer research. 

2021 Session Chair

Dr. Eduardo Bonavita

Dr. Bonavita is a senior PostDoc at CRUK Manchester Institute in the laboratory of Dr. Santiago Zelenay where he is investigating the opposing role of inflammation during cancer. Dr Bonavita has published landmark studies addressing the role of inflammation in modulating anti-tumor immunity. 

2021 Early-Career Researcher Speakers

Dr. Matthias Bozza

Postdoctoral Research Fellow, German Cancer Research Centre, Heidelberg, Germany

"Non-viral, autonomously replicating DNA Nanovectors for T-cells engineering"

Dr. Rahul Mirlekar

Postdoctoral Research Fellow, University of North Carolina at Chapel Hill, USA

"IL-35+ B cells establish immunosuppressive network in pancreatic ductal adenocarcinoma"

Maria Davern

PhD Student, Trinity College Dublin, Ireland

"The impact of major oncologic surgery on immune responses in the immediate post-operative setting in oesophageal adenocarcinoma patients; a guide to harnessing the double-edged sword of cancer surgery"

Dr. Ramona Moles

Postdoctoral Research Fellow, National Cancer Institute, Bethesda, USA

"Depletion of Innate Myeloid and NK cells exacerbates HTLV-1 infection and rescues the infectivity of the HTLV-1 orf-I knock-out virus"